CLCharlotte Duch Lynggaard

Charlotte Duch Lynggaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charlotte Duch Lynggaard has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The 2024 International Society of Oral Oncology-Multinational Association of Supportive Care in Cancer-American Society of Clinical Oncology guidelines for the prevention and management of osteoradionecrosis of the jaw

    by Derek K. Smith, Alessandro Villa, Shlomo A. Koyfman, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Lone E. Forner, Clifton David Fuller, Yvonne M. Mowery, Barbara A. Murphy, et al.


  • Open Access

    Supplementary Data 1 from Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial

    by Amanda-Louise Fenger Carlander, Kathrine Kronberg Jakobsen, Tobias Todsen, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Jens Kastrup, Jeppe Friborg, Charlotte Duch Lynggaard, Anne Werner Hauge, et al.

  • Open Access

    Data from Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial

    by Amanda-Louise Fenger Carlander, Kathrine Kronberg Jakobsen, Tobias Todsen, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Jens Kastrup, Jeppe Friborg, Charlotte Duch Lynggaard, Anne Werner Hauge, et al.

    Purpose:The long-term effect of adipose-derived mesenchymal stromal cells (ASC) on restoring radiation-induced salivary gland hypofunction in patients with previous head and neck cancer has not been validated in larger settings.Patients and Methods:The study was a 12-month follow-up of a randomized trial, including patients with hyposalivation. Patients were randomized to receive allogeneic ASC or placebo in the submandibular glands. The primary endpoint was unstimulated whole saliva (UWS) followed by stimulated whole saliva, patient-reported outcomes (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Head and Neck Module, and the xerostomia questionnaire), and safety.Results:Of the 120 enrolled patients, 117 (97.5%) were assessed at 12 months. Treatment with ASC did not increase UWS compared with placebo: Increase in UWS was 0.02 mL/minute [95% confidence interval (CI), 0.01–0.04] in the ASC group and 0.02 mL/minute (95% CI, 0–0.03) in the placebo group (P = 0.56). ASC reduced the symptom burden for dry mouth with −10.07 units (95% CI, −13.39 to −6.75) compared with −4.15 units (95% CI, −7.46 to −0.84) in the placebo group (P = 0.01). Compared with placebo, ASC did not improve sticky saliva (−9.27 vs. −4.55 units; P = 0.13), swallowing (−4.50 vs. 3.49 units; P = 0.5), or xerostomia (−3.12 vs. −2.74 units; P = 0.82). Treatment was safe and associated with a transient immune response.Conclusions:Intraglandular ACS therapy in the submandibular glands significantly relieved subjective dry mouth symptoms. Both ASC and placebo increased UWS, but ASC did not prove superior to placebo in restoring salivary gland function, based on the salivary flow rate.

  • Long-term Effectiveness and Safety of Mesenchymal Stromal Cell Therapy for Radiation-Induced Hyposalivation in Head and Neck Cancer Survivors: A Randomized Phase II Trial

    by Amanda-Louise Fenger Carlander, Kathrine Kronberg Jakobsen, Tobias Todsen, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Jens Kastrup, Jeppe Friborg, Charlotte Duch Lynggaard, Anne Werner Hauge, et al.

    Purpose: The long-term effect of adipose-derived mesenchymal stromal cells (ASC) on restoring radiation-induced salivary gland hypofunction in patients with previous head and neck cancer has not been validated in larger settings. Patients and Methods: The study was a 12-month follow-up of a randomized trial, including patients with hyposalivation. Patients were randomized to receive allogeneic ASC or placebo in the submandibular glands. The primary endpoint was unstimulated whole saliva (UWS) followed by stimulated whole saliva, patient-reported outcomes (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Head and Neck Module, and the xerostomia questionnaire), and safety. Results: Of the 120 enrolled patients, 117 (97.5%) were assessed at 12 months. Treatment with ASC did not increase UWS compared with placebo: Increase in UWS was 0.02 mL/minute [95% confidence interval (CI), 0.01–0.04] in the ASC group and 0.02 mL/minute (95% CI, 0–0.03) in the placebo group (P = 0.56). ASC reduced the symptom burden for dry mouth with −10.07 units (95% CI, −13.39 to −6.75) compared with −4.15 units (95% CI, −7.46 to −0.84) in the placebo group (P = 0.01). Compared with placebo, ASC did not improve sticky saliva (−9.27 vs. −4.55 units; P = 0.13), swallowing (−4.50 vs. 3.49 units; P = 0.5), or xerostomia (−3.12 vs. −2.74 units; P = 0.82). Treatment was safe and associated with a transient immune response. Conclusions: Intraglandular ACS therapy in the submandibular glands significantly relieved subjective dry mouth symptoms. Both ASC and placebo increased UWS, but ASC did not prove superior to placebo in restoring salivary gland function, based on the salivary flow rate.


  • Top Cited Papers

    Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline

    by Douglas E. Peterson, Shlomo A. Koyfman, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Lone E. Forner, Clifton David Fuller, Yvonne M. Mowery, Barbara A. Murphy, Erin Watson, et al.

    ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer. METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023. The guideline also incorporated systematic reviews conducted by ISOO-MASCC, which included studies published from January 1, 1990, through December 31, 2008. RESULTS: A total of 1,539 publications were initially identified. There were 487 duplicate publications, resulting in 1,052 studies screened by abstract, 104 screened by full text, and 80 included for systematic review evaluation. RECOMMENDATIONS: Due to limitations of available evidence, the guideline relied on informal consensus for some recommendations. Recommendations that were deemed evidence-based with strong evidence by the Expert Panel were those pertaining to best practices in prevention of ORN and surgical management. No recommendation was possible for the utilization of leukocyte- and platelet-rich fibrin or photobiomodulation for prevention of ORN. The use of hyperbaric oxygen in prevention and management of ORN remains largely unjustified, with limited evidence to support its practice. Additional information is available at www.asco.org/head-neck-cancer-guidelines .


  • Open Access

    Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia

    by Kathrine Kronberg Jakobsen, Charlotte Duch Lynggaard, Natasja Paaske, Amanda-Louise Fenger Carlander, Jens Kastrup, Anne Werner Hauge, Robin Christensen, Christian Grønhøj, Christian von Buchwald

    Background: Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment. The study evaluated the long-term safety and effectiveness of allogeneic ASCs in radiation-induced xerostomia among patients with previous oropharyngeal cancer. Methods: This study constitutes 3-year follow-up on the original 10 patients who received allogeneic ASCs injections to the submandibular and parotid glands as part of the MESRIX-II trial. The MESRIX-II trial included the preliminary 4-month follow-up. The primary endpoint was long-term safety. Secondary endpoints were effectiveness evaluated by changes in salivary flow rate and patient-reported outcomes (PROs). Immune response was evaluated by assessing the development of donor-specific antibodies (DSA). Findings: All 10 MESRIX-II patients completed the long-term follow-up (ie, no missing data). During the long-term follow-up, 2 patients encountered a significant adverse event, which was determined to be unrelated to the treatment. No DSAs were detectable at 3 years. The stimulated salivary flow rate increased significantly from an average of 0.66 mL/minute at baseline to 0.86 mL/minute at follow-up, corresponding to an increase of 0.20 [95% CI 0.08 to 0.30] mL/minute, or approximately 30%. Among the PROs, sticky saliva symptoms were reduced, with a −20.0 [95% CI −37.3 to −2.7] units. Interpretation: In conclusion, this study is the first to present long-term follow-up outcomes of allogeneic ASC treatment as a therapeutic option for radiation-induced xerostomia. The study found that ASC treatment appears safe, and there were no indications of adverse immune responses at the 3-year follow-up. Further studies are warranted to evaluate the findings in larger settings.


  • Open Access

    Supplementary Data 1 from Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial

    by Kathrine Kronberg Jakobsen, Amanda-Louise Fenger Carlander, Tobias Todsen, Jacob Melchiors, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Christine Mordhorst, Helene Stampe, Jens Kastrup, et al.

  • Open Access

    Supplementary Data 1 from Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial

    by Kathrine Kronberg Jakobsen, Amanda-Louise Fenger Carlander, Tobias Todsen, Jacob Melchiors, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Christine Mordhorst, Helene Stampe, Jens Kastrup, et al.

  • Open Access

    Data from Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial

    by Kathrine Kronberg Jakobsen, Amanda-Louise Fenger Carlander, Tobias Todsen, Jacob Melchiors, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Christine Mordhorst, Helene Stampe, Jens Kastrup, et al.

    Purpose:No effective treatment exists for radiation-induced xerostomia. The objective of this study was to compare the effect of adipose-derived mesenchymal stem/stromal cell (ASC) injection, relative to placebo, on salivary gland function in patients with radiation-induced xerostomia.Patient and Methods:In this single-centre, double-blind, placebo-controlled trial, patients with hyposalivation were randomised to receive ultrasound-guided injections of allogeneic ASCs or placebo into the submandibular glands. Patients were followed for 4 months. We evaluated unstimulated whole salivary flow rate (UWS), stimulated salivary flow rate, and patient-reported outcomes. Adverse events were recorded and immune response determined in blood samples.Results:We enrolled 120 patients. ASC treatment resulted in a statistically significant UWS increase of 0.04 [95% confidence interval (CI), 0.02–0.06] mL/min (38%) compared with pretreatment baseline whereas placebo treatment did not cause a significant increase [0.01 (95% CI, −0.01 to 0.04) mL/min (21%)]. Both the ASC and placebo treatment yielded notable symptom reductions, with dry mouth decreasing by 13.6 and 7.7 units, sticky saliva decreased by 14.8 and 9.3 units, swallowing difficulties decreased by 7.9 and 8.0 units, and the summary score of the Xerostomia Questionnaire decreased 5.9 and 5.1 units for the ASC and placebo arms, respectively. We found no statistically significant group difference between the ASC and placebo arms for any of the outcomes.Conclusions:We could not confirm superiority of the ASC relative to placebo. ASC therapy significantly improved UWS in previous patients with head and neck cancer, whereas placebo resulted in an insignificant increase.

  • Open Access

    Data from Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial

    by Kathrine Kronberg Jakobsen, Amanda-Louise Fenger Carlander, Tobias Todsen, Jacob Melchiors, Natasja Paaske, Anne Kathrine Østergaard Madsen, Simone Kloch Bendtsen, Christine Mordhorst, Helene Stampe, Jens Kastrup, et al.

    Purpose:No effective treatment exists for radiation-induced xerostomia. The objective of this study was to compare the effect of adipose-derived mesenchymal stem/stromal cell (ASC) injection, relative to placebo, on salivary gland function in patients with radiation-induced xerostomia.Patient and Methods:In this single-centre, double-blind, placebo-controlled trial, patients with hyposalivation were randomised to receive ultrasound-guided injections of allogeneic ASCs or placebo into the submandibular glands. Patients were followed for 4 months. We evaluated unstimulated whole salivary flow rate (UWS), stimulated salivary flow rate, and patient-reported outcomes. Adverse events were recorded and immune response determined in blood samples.Results:We enrolled 120 patients. ASC treatment resulted in a statistically significant UWS increase of 0.04 [95% confidence interval (CI), 0.02–0.06] mL/min (38%) compared with pretreatment baseline whereas placebo treatment did not cause a significant increase [0.01 (95% CI, −0.01 to 0.04) mL/min (21%)]. Both the ASC and placebo treatment yielded notable symptom reductions, with dry mouth decreasing by 13.6 and 7.7 units, sticky saliva decreased by 14.8 and 9.3 units, swallowing difficulties decreased by 7.9 and 8.0 units, and the summary score of the Xerostomia Questionnaire decreased 5.9 and 5.1 units for the ASC and placebo arms, respectively. We found no statistically significant group difference between the ASC and placebo arms for any of the outcomes.Conclusions:We could not confirm superiority of the ASC relative to placebo. ASC therapy significantly improved UWS in previous patients with head and neck cancer, whereas placebo resulted in an insignificant increase.